Molecular Templates Inc Stock News

The company is taking back rights to one drug candidate and discontinuing development of another.

Molecular Templates Inc (NASDAQ: MTEM) has decided to discontinue the development of MT-3724, its only first-generation engineered toxin bodies (ETB), and focus its resources on the development of

Molecular Templates to Assume Full Rights to TAK-169, Second Generation ETB Targeting CD38 for the Treatment of Multiple Myeloma

AUSTIN, Texas, March 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discove

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week

Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly owned hosp

AUSTIN, Texas, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery a

Molecular Templates to receive $70 million upfront payment with potential for additional milestone and royalty payments on future sales Molecular Templates to receive $70 million upfront payment with

Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begi

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery

AUSTIN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focuse

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin

AUSTIN, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focuse

AUSTIN, Texas, July 20, 2020 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on.